LISATA THERAPEUTICS INC(LSTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LSTA LISATA THERAPEUTICS INC

Market Closed 12-12 16:00:00 EST

2.00

-0.04

-1.96%

盘后2.09

+0.09+4.40%

18:17 EST

High2.15	Low1.98	Vol13.82K
Open1.98	D1 Closing2.04	Amplitude8.33%
Mkt Cap17.64M	Tradable Cap14.52M	Total Shares8.82M
T/O28.09K	T/O Rate0.19%	Tradable Shares7.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LSTA","market":"US","secType":"STK","nameCN":"LISATA THERAPEUTICS INC","latestPrice":2,"timestamp":1765573200000,"preClose":2.04,"halted":0,"volume":13815,"hourTrading":{"tag":"盘后","latestPrice":2.0881,"preClose":2,"latestTime":"18:17 EST","volume":157,"amount":323.91,"timestamp":1765581459353},"delay":0,"floatShares":7259686,"shares":8820733,"eps":-2.124745,"marketStatus":"Market Closed","change":-0.04,"latestTime":"12-12 16:00:00 EST","open":1.98,"high":2.15,"low":1.98,"amount":28090.130678999998,"amplitude":0.083333,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.124745,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"listingDate":1186632000000,"exchange":"NASDAQ","adjPreClose":2.04,"preHourTrading":{"tag":"盘前","latestPrice":2,"preClose":2.04,"latestTime":"09:28 EST","volume":406,"amount":818.3499618,"timestamp":1765549693359},"postHourTrading":{"tag":"盘后","latestPrice":2.0881,"preClose":2,"latestTime":"18:17 EST","volume":157,"amount":323.91,"timestamp":1765581459353},"volumeRatio":0.608552775944609},"requestUrl":"/m/hq/s/LSTA/wiki","defaultTab":"wiki","newsList":[{"id":"2584621613","title":"First Berlin Equity Research Reiterates Buy Rating on Lisata Therapeutics With USD 15 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2584621613","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584621613?lang=en_us&edition=fundamental","pubTime":"2025-11-17 22:19","pubTimestamp":1763389198,"startTime":"0","endTime":"0","summary":"First Berlin Equity Research has published an updated report on Lisata Therapeutics Inc., maintaining its \"Buy\" rating and a 12-month price target of $15 per share. Analyst Christian Orquera highlighted that Lisata's results for the first nine months of 2025 slightly exceeded expectations, driven by reduced operational expenses and disciplined R&D spending. The report noted progress in Lisata's certepetide platform and strong cash reserves, providing a runway into the first quarter of 2027. First Berlin expects further milestones to support a potential re-rating of the stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via EQS News, a service of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL8WBw5v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"gpt_icon":0},{"id":"1154873083","title":"Lisata Q3 2025 Earnings Call Summary and Q&A Highlights: Strategic Alliances and Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1154873083","media":"Earnings Call","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154873083?lang=en_us&edition=fundamental","pubTime":"2025-11-09 13:21","pubTimestamp":1762665673,"startTime":"0","endTime":"0","summary":"[Management View]Lisata Therapeutics reported significant progress in clinical and corporate initiatives, including a notable reduction in operating expenses and a strengthened capital position. Key...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA"],"gpt_icon":0},{"id":"2582893727","title":"Lisata (LSTA) Q3 2025 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2582893727","media":"Motley Fool Transcribing","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582893727?lang=en_us&edition=fundamental","pubTime":"2025-11-09 13:19","pubTimestamp":1762665570,"startTime":"0","endTime":"0","summary":"Image source: The Motley Fool.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_motley_transcript","url":"https://www.fool.com/earnings/call-transcripts/2025/11/09/lisata-lsta-q3-2025-earnings-call-transcript/","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2025/11/09/lisata-lsta-q3-2025-earnings-call-transcript/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_motley_transcript","symbols":["LSTA"],"gpt_icon":0},{"id":"2581049892","title":"Lisata Therapeutics Q3 net loss narrows to $4.2 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581049892","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581049892?lang=en_us&edition=fundamental","pubTime":"2025-11-07 06:17","pubTimestamp":1762467474,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics Q3 net loss narrows to $4.2 mlnOverviewLisata Q3 net loss narrows to $4.2 mln from $4.9 mln yr/yrOperating expenses decreased by 17.3% to $4.4 mln in Q3 2025Cash runway extended in","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1M0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"gpt_icon":0},{"id":"2581048703","title":"Lisata Therapeutics Q3 EPS USD -0.49","url":"https://stock-news.laohu8.com/highlight/detail?id=2581048703","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581048703?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:26","pubTimestamp":1762464417,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Lisata Therapeutics Q3 operating expenses USD 4.414 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202521:05:55.35 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nRSD1Y0nMp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LSTA"],"gpt_icon":0},{"id":"2581795618","title":"Lisata Therapeutics Inc  expected to post a loss of 53 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581795618","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581795618?lang=en_us&edition=fundamental","pubTime":"2025-11-05 07:08","pubTimestamp":1762297699,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics Inc  expected to post a loss of53cents a share - Earnings Preview Lisata Therapeutics Inc LSTA.OQ LSTA.O is expected to  show no change in quarterly revenue when it reports  result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG3PO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"gpt_icon":0},{"id":"2581766065","title":"Lisata Therapeutics Reports Positive Preclinical Results for Certepetide in ADC Combinations","url":"https://stock-news.laohu8.com/highlight/detail?id=2581766065","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581766065?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:00","pubTimestamp":1762290013,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics Inc. has announced positive preclinical results from studies evaluating its proprietary iRGD cyclic peptide product candidate, certepetide, as part of antibody-drug conjugate  combinations. The results were presented by Lisata's licensing partner, Catalent, Inc., at the 16th Annual World ADC San Diego Conference, held November 3-6, 2025. Data from Catalent's studies showed that incorporating certepetide as a non-cytotoxic payload in its SMARTag ADC technology improved tumor-selective penetration and efficacy, and broadened the distribution of the cytotoxic payload within the tumor microenvironment. The findings reinforce evidence that certepetide can enhance the targeting and effectiveness of therapeutic agents in which it is incorporated or co-administered.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informatio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDLNJMbY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LSTA","LU0314104364.USD","IE00B3QW5Z07.USD","BK4112","LU2095319765.USD","BK4139","LU2210149790.SGD","IE00BGHQF748.EUR","BK4585","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2575405110","title":"Lisata Therapeutics to Present Corporate Overview at LD Micro Main Event XIX Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2575405110","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575405110?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:01","pubTimestamp":1760356875,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics Inc., a clinical-stage pharmaceutical company focused on therapies for advanced solid tumors and other serious diseases, will present a corporate overview at the LD Micro Main Event XIX Conference in San Diego, California. The presentation is scheduled for Monday, October 20, 2025, at 10:30 a.m. Pacific time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via Newsfile  on October 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL3Gct1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","BK4139"],"gpt_icon":0},{"id":"2573923214","title":"Lisata Therapeutics announces global license agreement with Catalent for certepetide use in antibody drug conjugates","url":"https://stock-news.laohu8.com/highlight/detail?id=2573923214","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573923214?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:30","pubTimestamp":1759926620,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics Inc. has announced a global product license agreement with Catalent, Inc. Under the terms of the agreement, Catalent gains worldwide, non-exclusive rights to develop and commercialize bioconjugate products containing certepetide and its analogs, including the right to collaborate with third parties. Catalent will evaluate certepetide and its analogs as SMARTag payloads in clinical studies across multiple antibody-drug conjugates  targeting difficult-to-treat diseases. Lisata is eligible to receive over $10 million in tiered study initiation milestone payments as well as revenue sharing on future sales and partnerships.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL14rSl2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LSTA","LU0314104364.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4139","NDAQ","LU2095319765.USD","LU2210149790.SGD","BK4588","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2573923229","title":"Lisata Therapeutics Inc - to Receive Over $10 Mln in Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2573923229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573923229?lang=en_us&edition=fundamental","pubTime":"2025-10-08 20:30","pubTimestamp":1759926600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nTUABW57RP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LSTA"],"gpt_icon":0},{"id":"2571338178","title":"Lisata Therapeutics Announces Encouraging Preliminary Results from CENDIFOX Trial of Certepetide in Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2571338178","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571338178?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:00","pubTimestamp":1759147242,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics Inc. has announced encouraging preliminary results from the pancreatic ductal adenocarcinoma  cohort of its Phase 1/2a CENDIFOX trial . The study is evaluating the company's investigational iRGD cyclic peptide product candidate, certepetide , in combination with FOLFIRINOX-based therapies for the treatment of pancreatic, colon, and appendiceal cancers. These initial findings suggest that certepetide may enhance the effectiveness of standard-of-care chemotherapy in patients with resectable and borderline resectable PDAC. The results will be presented in poster A070 at the American Association for Cancer Research  Special Conference in Cancer Research: Advances in Pancreatic Cancer Research-Emerging Science Driving Transformative Solutions, scheduled for September 29, 2025, in Boston, Massachusetts. The full abstract is available on the AACR website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT str","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL9FlkGt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2210150020.SGD","LU2095319765.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4585","BK4588","NDAQ","LU0314104364.USD","LSTA","BK4139","IE00B64PRP62.GBP","BK4112","LU2210149790.SGD"],"gpt_icon":0},{"id":"2571338433","title":"Lisata Therapeutics Announces Encouraging Preliminary Results From the Pancreatic Cancer Cohort of the Cendifox Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2571338433","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571338433?lang=en_us&edition=fundamental","pubTime":"2025-09-29 20:00","pubTimestamp":1759147203,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nTUAJLYQ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LSTA","BK4139"],"gpt_icon":0},{"id":"2561642384","title":"Lisata Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2561642384","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2561642384?lang=en_us&edition=fundamental","pubTime":"2025-08-21 19:29","pubTimestamp":1755775740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LSTA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 21, 2025 07:29 ET (11:29 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA","LENZ"],"gpt_icon":0},{"id":"2560904282","title":"First Berlin Equity Research Reiterates \"Buy\" Rating for Lisata Therapeutics Inc. with USD 15.00 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2560904282","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2560904282?lang=en_us&edition=fundamental","pubTime":"2025-08-18 19:41","pubTimestamp":1755517281,"startTime":"0","endTime":"0","summary":"First Berlin Equity Research GmbH has reaffirmed its BUY recommendation for Lisata Therapeutics Inc., setting a 12-month target price of USD 15.00. Analyst Christian Orquera highlighted the company's slightly better-than-expected H1/25 financial results and promising developments in their pancreatic cancer treatments. The ASCEND phase 2b trial showed positive outcomes for the combination of certepetide and standard chemotherapy, enhancing confidence in the treatment's efficacy. The final trial results are anticipated in Q1 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lisata Therapeutics Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG , on August 18, 2025, and is solel","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250818:nNDL1x34Gn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA"],"gpt_icon":0},{"id":"2557511176","title":"Lisata Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2557511176","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557511176?lang=en_us&edition=fundamental","pubTime":"2025-08-08 11:41","pubTimestamp":1754624466,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryLisata Therapeutics Inc LSTA.OQ reported a quarterly adjusted loss of 54 cents per share for the quarter ended J","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nL8N3U00CN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA"],"gpt_icon":0},{"id":"2557157599","title":"Lisata Therapeutics Inc - Projects Cash Runway Into Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2557157599","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557157599?lang=en_us&edition=fundamental","pubTime":"2025-08-08 04:05","pubTimestamp":1754597104,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nTUABZXMJL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LSTA"],"gpt_icon":0},{"id":"2557055305","title":"TotalEnergies Decides Against Investing in Train 5 at NextDecade's Rio Grande LNG Project, Sources Say","url":"https://stock-news.laohu8.com/highlight/detail?id=2557055305","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557055305?lang=en_us&edition=fundamental","pubTime":"2025-08-06 23:47","pubTimestamp":1754495279,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250806:nL8N3TX2HN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4023","BK4144","BK4139","NEXT","VG","LSTA","BK4213"],"gpt_icon":0},{"id":"2557314669","title":"Lisata Therapeutics Inc  expected to post a loss of 65 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2557314669","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557314669?lang=en_us&edition=fundamental","pubTime":"2025-08-06 04:39","pubTimestamp":1754426344,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics Inc  expected to post a loss of65cents a share - Earnings Preview Lisata Therapeutics Inc LSTA.OQ LSTA.O is expected to  show no change in quarterly revenue when it reports  result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250805:nL8N3TX2Z6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LSTA"],"gpt_icon":0},{"id":"2552148606","title":"Lisata Therapeutics Inc. Completes Enrollment for iLSTA Trial, Reports Promising Preliminary Data on Certepetide in Treating Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2552148606","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552148606?lang=en_us&edition=fundamental","pubTime":"2025-07-17 20:00","pubTimestamp":1752753641,"startTime":"0","endTime":"0","summary":"Lisata Therapeutics Inc. Completes Enrollment for iLSTA Trial, Reports Promising Preliminary Data on Certepetide in Treating Pancreatic Cancer. Lisata Therapeutics Inc. and WARPNINE have announced the completion of patient enrollment for the Phase 1b/2a iLSTA trial in Australia. The study is evaluating Lisata's proprietary iRGD cyclic peptide product candidate, certepetide, in combination with standard-of-care chemotherapy and immunotherapy for treating locally advanced non-resectable pancreatic ductal adenocarcinoma . Preliminary data presented at ESMO-GI indicated a 60% overall response rate and a 100% overall disease control rate. Final results from the study are anticipated in the future, with the potential to offer a new treatment option for patients with locally advanced PDAC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for infor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250717:nNDL8td2G3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","IE00B64PRP62.GBP","LSTA","LU2210150020.SGD","NDAQ","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","BK4139","BK4585","BK4112","BK4588"],"gpt_icon":0},{"id":"2551195707","title":"Lisata Therapeutics Is Maintained at Buy by Brookline Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2551195707","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551195707?lang=en_us&edition=fundamental","pubTime":"2025-07-15 23:33","pubTimestamp":1752593580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/LSTA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 15, 2025 11:33 ET (15:33 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRKL","LSTA","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lisata.com","stockEarnings":[{"period":"1week","weight":0.0152},{"period":"1month","weight":-0.0741},{"period":"3month","weight":-0.0868},{"period":"6month","weight":-0.1984},{"period":"1year","weight":-0.2674},{"period":"ytd","weight":-0.3289}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.14046},{"month":2,"riseRate":0.4,"avgChangeRate":-0.026263},{"month":3,"riseRate":0.7,"avgChangeRate":0.033941},{"month":4,"riseRate":0.3,"avgChangeRate":-0.098618},{"month":5,"riseRate":0.3,"avgChangeRate":-0.006081},{"month":6,"riseRate":0.6,"avgChangeRate":0.073889},{"month":7,"riseRate":0.181818,"avgChangeRate":-0.054717},{"month":8,"riseRate":0.090909,"avgChangeRate":-0.092076},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.026365},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.098229},{"month":11,"riseRate":0.454545,"avgChangeRate":-0.024316},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.077438}],"exchange":"NASDAQ","name":"LISATA THERAPEUTICS INC","nameEN":"LISATA THERAPEUTICS INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LISATA THERAPEUTICS INC(LSTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LISATA THERAPEUTICS INC(LSTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LISATA THERAPEUTICS INC,LSTA,LISATA THERAPEUTICS INC股票,LISATA THERAPEUTICS INC股票老虎,LISATA THERAPEUTICS INC股票老虎国际,LISATA THERAPEUTICS INC行情,LISATA THERAPEUTICS INC股票行情,LISATA THERAPEUTICS INC股价,LISATA THERAPEUTICS INC股市,LISATA THERAPEUTICS INC股票价格,LISATA THERAPEUTICS INC股票交易,LISATA THERAPEUTICS INC股票购买,LISATA THERAPEUTICS INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LISATA THERAPEUTICS INC(LSTA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LISATA THERAPEUTICS INC(LSTA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction